USFDA concludes inspection at Piramal Pharma, issues EIR

Piramal Pharma said the US health regulator issued an Establishment Inspection Report (EIR) for its Sellersville manufacturing facility in Pennsylvania.

236
USFDA Inspection
USFDA Inspection

Last Updated on November 11, 2024 by The Health Master

The US Food and Drug Administration (USFDA) has concluded its inspection of Piramal Pharma’s Sellersville manufacturing facility in the United States, the pharmaceutical firm said on April 19.

Piramal Pharma said the US health regulator issued an Establishment Inspection Report (EIR) for its Sellersville manufacturing facility in Pennsylvania.

EIR is the final inspection report of an USFDA inspection.

The inspection was conducted between December 19, 2022 and January 13, 2023.

Piramal Pharma’s Sellersville facility is a fully integrated site, which is involved in the manufacturing and packaging of solid oral dosage forms, liquids, creams and ointments.

Meanwhile, USFDA issued an EIR also for Piramal Pharma’s Lexington unit, in February.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news